Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone in Obese Type 2 Diabetic Patients With HFpEF
NCT05838287Phase 4Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Jul 2023
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Pioglitazone Administration Group with Placebo/Control Group (2 arms). Primary endpoints: Change in Systolic function at 24 weeks and Change in Diastolic function at 24 weeks. Started Jul 2023; status: recruiting.
02
Drugs
pioglitazone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05838287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838287.